Journal article
Lenvatinib Plus Pembrolizumab Versus Sunitinib in First-Line Treatment of Advanced Renal Cell Carcinoma: Final Prespecified Overall Survival Analysis of CLEAR, a Phase III Study
Abstract
Clinical trials frequently include multiple end points that mature at different times. The initial report, typically based on the primary end point, may be published when key planned co-primary or secondary analyses are not yet available. Clinical trial updates provide an opportunity to disseminate additional results from studies, published in JCO or elsewhere, for which the primary end point has already been reported.We present the final …
Authors
Motzer RJ; Porta C; Eto M; Powles T; Grünwald V; Hutson TE; Alekseev B; Rha SY; Merchan J; Goh JC
Journal
Journal of Clinical Oncology, Vol. 42, No. 11, pp. 1222–1228
Publisher
American Society of Clinical Oncology (ASCO)
Publication Date
April 10, 2024
DOI
10.1200/jco.23.01569
ISSN
0732-183X